News Sentiment

OSRH sentiment intelligence

OSR Holdings Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 50 Balanced news tone 17 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 0.47 Week of 17 Jul 2026
Weighted tone 50/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Earnings

75/100 classification confidence.

Company focus 6

directly relevant articles

Source quality 0

high-authority source matches

Trend context Trend inactive

+42.3% over one week, +19.2% over four weeks, trend inactive, and below fair value.

Latest direct headline Neutral

Form DEF 14A OSR Holdings Inc For: 16 July By Investing.com

Market Reaction

Price moving ahead of tone

56/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Earnings 75/100 classification
One-week reaction 42.3% Price confirming higher
Trend fit Trend inactive 19.2% over four weeks
Fair value -92.3% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 1
Neutral 15
Negative 1

Relevance

Why the article matched

Direct first
Direct company coverage 6
Industry context 9
Sector context 2

Sources

Coverage mix

Publishers
Market source 6
Stock Titan 2
simplywall.st 2
SPACInsider 2
Investing.com Canada 1
TradingView 1
PR Newswire 1
MarketBeat 1

Event Lens

What the news is about

Classified themes
Earnings 8
Deals and strategy 5
Market update 4

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-17 of 17
SPACInsider Sector context

Bellevue Life Sciences Acquisition Corp. (BLAC) to Combine with OSR Holdings

Bellevue Life Sciences (NASDAQ:BLAC) has entered into a definitive agreement to combine with OSR Holdings, a Korean healthcare holding company. This merger involves a sponsor entity merging with itself, as both Bellevue and OSR share CEO Peter Kuk Hyoun Hwang, who is also the fou

Tone
Neutral 50/100
Event
Deals and strategy
Published
17 Nov 2023 11:14
Source
SPACInsider
MarketBeat Direct company coverage

Bellevue Life Sciences Acquisition (BLAC) 10K Form and Latest SEC Filings 2026

This article provides an overview of OSR Holdings, Inc.'s (NASDAQ: OSRH) SEC filings, highlighting that the company has submitted over 133 documents since 2022. It details different types of SEC filings such as 10-K, 10-Q, and 8-K, explaining their significance for investors. The

Tone
Neutral 50/100
Event
Deals and strategy
Published
02 Oct 2023 17:09
Source
MarketBeat
Fierce Biotech Sector context

South Korean biotech group spies US SPAC as route to Nasdaq

South Korean biotech OSR Holdings plans to go public on the Nasdaq through a merger with the US-based SPAC Bellevue Life Sciences Acquisition. OSR, a global healthcare holding company, has oncology and osteoarthritis drug development operations in South Korea and Switzerland. The

Tone
Neutral 50/100
Event
Deals and strategy
Published
12 Jul 2023 08:45
Source
Fierce Biotech
Stock Titan Direct company coverage

BLAC - Bellevue Life Sciences Acquisition Corp Latest Stock News & Market Updates

This page provides news and updates for Bellevue Life Sciences Acquisition Corp. (BLAC), detailing its transformation into OSR Holdings, Inc. and its subsequent trading as OSRH on Nasdaq. The content highlights key milestones such as the business combination, name change, and OSR

Tone
Neutral 50/100
Event
Deals and strategy
Published
11 Jul 2023 20:09
Source
Stock Titan
SPACInsider Industry context

Bellevue Life Sciences Acquisition Corp. (BLACU) Prices $60M IPO

Bellevue Life Sciences Acquisition Corp. has priced its $60 million IPO, with units expected to trade on Nasdaq under "BLACU." The SPAC intends to target the biotechnology sector within the healthcare industry, focusing on next-generation biologics. This offering adds to the 2023

Tone
Neutral 50/100
Event
Deals and strategy
Published
09 Feb 2023 17:55
Source
SPACInsider